1. Generics Bulletin
  2. >>Products

Nova Scotia Becomes Sixth Jurisdiction To Implement Biosimilar Switching

Policy Welcomed By Trade And Advocacy Groups

 
• By Chloe Kent

Citizens enrolled on Nova Scotia’s Pharmacare programs have 12 months to switch to biosimilar versions of certain biologic drugs, including some insulins and medications used to treat Crohn’s disease and rheumatoid arthritis. 

Nova Scotia flag
Seven biosimilars have been included in the initial policy • Source: Alamy

Nova Scotia has become the sixth Canadian jurisdiction and fifth province to implement a biosimilar switching policy in its public health program, a move which is expected to save the local government an estimated CAD13m ($10.2m) annually.

The Nova Scotia announcement follows the implementation of similar policies in British Columbia, Alberta, New Brunswick and Quebec. A fifth...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products